Systemic lupus erythematosus (SLE), also called lupus, is an autoimmune disorder characterized by the immune system attacking the body's own tissues and organs, leading to inflammation and damage. The severity of the disease varies, from mild cases only involving the skin to severe cases affecting multiple organs, including the brain. Lupus sufferers experience flares, or intervals of active disease, and remissions in disease. The disease most predominantly occurs in women of childbearing age, but also affects children, adolescents, and men. While the cause of lupus is still unknown, various genetic, environmental, and infectious causes have been associated with its development. Current treatments for lupus vary depending on the extent of the disease, and may change over time. Some medications used to ease symptoms include nonsteroidal anti-inflammatory drugs, antimalarial drugs, corticosteroids, and immunosuppressive medications, though many of these drugs carry their own risks.
What is Lupus?
Lupus, also called systemic lupus erythematosus or SLE, is a disease that affects your immune system. Normally, your immune system fights infections caused by germs.
The World Health Organization (WHO) suspended the hydroxychloroquine trial amid the coronavirus pandemic. The decision comes after the study findings published in The Lancet reported issues on the drug's efficacy and safety. Now, the journal has issued a correction on the figures reported in the study.
Researchers at Uppsala University and Uppsala University Hospital have developed a new method to measure levels of the medication hydroxychloroquine in patients with rheumatic disease systemic lupus erythematosus (SLE).
The malaria drug hydroxychloroquine, which has been promoted as a potential treatment for Covid-19, is known to have potentially serious effects on heart rhythms.
A new study by investigators from Brigham and Women's Hospital examines changes in prescription patterns in the United States during the COVID-19 pandemic.
A large observational study suggests that treatment with the antimalarial drug chloroquine or its analog hydroxychloroquine (taken with or without the antibiotics azithromycin or clarithromycin) offers no benefit for patients with COVID-19.
COVID SHIELD is a major collaborative effort led by the Walter and Eliza Hall Institute of Medical Research in partnership with human data science company IQVIA.
Researchers from Prokhorov General Physics Institute of the Russian Academy of Sciences and the Moscow Institute of Physics and Technology have developed a novel method for diagnosing and monitoring autoimmune disorders.
Variants in a gene of the human immune system cause men and women to have different vulnerabilities to the autoimmune diseases lupus and Sjögren's syndrome, according to findings published in the journal Nature.
A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus disease 2019 (COVID-19).
The AIDS Clinical Trials Group, the world's largest and longest established HIV research network, today announced the initiation of ACTG 5395, a clinical trial to evaluate whether the drug combination hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19 (which is caused by infection with the virus SARS-CoV-2).
The Critical Path Institute and Provention Bio, Inc. are proud to announce their collaboration to significantly improve the scientific community's insight into type 1 diabetes through Provention's contribution of data from the Phase III Protégé study of teplizumab to the T1D Trial Outcome Measures Initiative integrated database.
Some diseases exhibit a clear sex bias, occurring more often, hitting harder or eliciting different symptoms in men or women.
Over the past few months, doctors resorted to repurposing medicines that have already been approved for other diseases to treat coronavirus patients. One drug that was widely used in the pandemic, hydroxychloroquine, has been found to be ineffective in treating the viral infection.
Working alongside colleagues in Mainz, Bern, Hannover and Bonn, researchers from Charité - Universitätsmedizin Berlin, the Berlin Institute of Health and the German Rheumatism Research Center Berlin were able to show how the microbiome helps to render the immune system capable of responding to pathogens.
Clinical leaders from the University of Kentucky's Markey Cancer Center, College of Medicine and College of Pharmacy have launched a clinical trial for experimental therapies to treat patients infected with COVID-19.
University of Houston Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, Chandra Mohan, and his team have discovered a difference in urinary biomarker proteins of lupus nephritis in patients according to race.
As researchers try to piece together a therapeutic strategy against the ongoing COVID-19 pandemic, a recent retrospective study from Cleveland Clinic Abu Dhabi, assessed the Hydroxychloroquine's efficacy in increasing SARS-CoV-2 viral clearance, finding that it appeared to significantly slow viral clearance in mild to moderately ill COVID-19 patients.
The disease course of COVID-19 is diverse, ranging from asymptomatic to fatal respiratory failure. Scientists have been working to uncover the immunological reasons behind this heterogeneity. A recent study on B cells, published on the preprint server medRxiv in April 2020, shows that extrafollicular B cells could be a marker of severe infection in the early stages, predicting the need for earlier immunomodulatory therapy.
Temple University Hospital is now participating in a variety of clinical trials that are testing investigational treatment options for patients diagnosed with the novel coronavirus, or COVID-19.
A new observational study by a group of scientists explores the rise in the public's fear-driven interest in unproven therapies for COVID-19, particularly chloroquine and hydroxychloroquine, by tracking the internet searches relating to the purchase of drugs in news reports or publicized by public figures. They conclude: "Stay grounded in evidence and fight misinformation." The research letter and accompanying editorial comment are published in the journal JAMA Internal Medicine.